| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Cancer and Infection Research, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
At the outset of the drug discovery program, two significant issues were recognized. First, because EGFR is one of four members of the type I family of RTKs, which share a high degree of sequence homology in their kinase domains, and because the type I receptors are themselves part of a much larger "superfamily" of RTKs, would it be possible to synthesize EGFR-selective inhibitors? Second, given that EGFR is commonly expressed in normal tissues as well as in tumors, would EGFR-targeted inhibitors cause unacceptable toxicity? The synthesis of tyrphostins that inhibit EGFR-TK activity without affecting insulin receptor TK activity provided an important precedent for a small-molecule synthetic approach (7) . The issue of toxicity could be addressed only with the inhibitors at hand, but attenuation, rather than complete blockade, of the abnormally active signal in tumors, implied by the high levels of EGFR expression, could provide an opportunity to define an acceptable therapeutic ratio between efficacy and toxicity.
This study was undertaken to examine the efficacy of ZD1839 for the growth inhibition of a range of human tumor xenografts based on a once-a-day p.o. dosing regimen and to evaluate the pharmacology of this targeted therapy.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
was synthesized as described by Barker et al. (6)
.
|
Cell Growth Assays.
A standard MTT assay was used to measure cell growth (11)
. Briefly, KB cells were seeded into 96-well culture plates (1.25 x 103 cells/well) in DMEM containing 5% (v/v) charcoal-treated FCS (to deplete endogenous growth factors), 2.0 mM L-glutamine, and 1% (v/v) nonessential amino acids; after attachment, cells were incubated for 72 h at 37°C with ZD1839 in the absence (control) or presence of EGF (10 ng/ml). After incubation, 15 µl of MTT (Sigma) solution (10 mg/ml) were added to each well, and the plates were then incubated for 1 h at 37°C. Medium was replaced with 100 µl of acid alcohol (90% ethanol, 5% acetic acid, 5% deionized water) per well. Absorbance at 540 nm was measured using a Titertek Multiscan. Cell growth was calculated by subtracting the mean day 0 absorbance value from the mean absorbance value at day 3. Cell growth inhibition was confirmed, with KB cells grown under similar conditions in 12-well dishes, by trypsinization and cell counting (Coulter) after 3 or 5 days of growth in the absence or presence of EGF and ZD1839 (0.05–25 µM). ZD1839 inhibition of EGF-, FGF- and VEGF-stimulated growth of HUVECs was measured as described (8)
. Briefly, HUVECs isolated from umbilical cords were seeded into 96-well plates (1 x 103 cells/well) and incubated for 4 days with ZD1839 in the absence or presence of EGF (10 ng/ml), FGF (0.3 ng/ml), or VEGF (3 ng/ml). Four h before harvesting, [3H]thymidine (1 µCi/ml) was added. After the medium was removed and the cells were washed with PBS/A, 20 µl of trypsin-EDTA (2.5% trypsin, 1.6 g/l EDTA) solution was added to each well. The cells were harvested by use of a 96-well plate harvester (TomTek) onto filtermats (Wallac Printed Filtermat A). Once dry, scintillation fluid was added (Wallac ß-plate Scint) to the filtermats, and they were assayed in a ß-plate scintillation counter (Wallac 1205 ß-plate liquid scintillation counter) for incorporation of 3H.
Tumor Xenograft Studies.
Female nude mice (Alderley Park strain, derived from Swiss nu/nu; AstraZeneca) approximately 8–10 weeks of age and weighing >18 g were used. Mice were housed in air-filtered laminar flow cabinets and handled using aseptic procedures with a 12-h light cycle and food and water ad libitum. Procedures involving animals and their care were conducted in accordance with the institutional guidelines that comply with United Kingdom national policies [Animals (Scientific Procedures) Act 1986]. Fragments of tumor tissue (A431, Du145, CR10, HCT15, HT29, HX62, P246, MDA-MB-231, and MCF-7) or tumor cells (A549, LoVo, KB, MIA PaCa2, MKN45, and AR42J) were injected or implanted s.c. (left flank) under anesthesia. Tumors were allowed to establish growth, and at a designated time after implantation, treatment with ZD1839 commenced. ZD1839 at doses of 3–200 mg/kg was administered p.o. once a day as a ball-milled suspension in 0.5% (v/v) polysorbate 80. Mice were monitored daily for signs of toxicity and were weighed regularly. The maximum dose of ZD1839 administered was 200 mg/kg; this dose did not induce any significant adverse effect on body weight or produce any other signs of toxicity. Tumor growth was assessed at intervals by caliper measurement of tumor diameter in the longest dimension (L) and at right angles to that axis (W). Tumor volume was estimated by the formula, 
/6 x L x W x W, for prolate ellipsoids, and efficacy was determined as percentage inhibition compared with vehicle-treated controls. To assess the pharmacodynamic action of ZD1839 treatment, A431 tumors were excised 6 h after the last of four daily doses of 0, 12.5, 50, and 200 mg/kg ZD1839 or at 2, 4, 6, 24, 30, and 36 h after a single 50 mg/kg dose. Total RNA was extracted from the tumors to quantify c-fos mRNA by reverse transcription-PCR.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Selectivity was demonstrated versus erbB2 and the VEGF TKs KDR and Flt-1, with at least a 100-fold difference in IC50 for EGFR compared with the other RTKs. Similarly, ZD1839 did not inhibit the activity of the serine-threonine kinases raf, MEK-1, and ERK-2 (MAPK). Enzyme kinetic studies to determine the characteristics of ZD1839 inhibition of EGFR TK (see Ref. 5
), in which peptide substrate concentration was fixed at 2 mM (
6-fold higher than the Km) and the ATP concentration was varied, showed that ZD1839 is a competitive inhibitor with respect to ATP (Ki = 2.1 ± 0.2 nM). Similarly, when the ATP concentration was fixed at 50 µM (6-fold higher than the Km) and peptide concentration was varied, ZD1839 showed noncompetitive kinetics (Ki = 15.0 ± 1.0 nM).
|
.
|
.
ZD1839 Inhibits EGFR Autophosphorylation.
Expression of phosphorylated EGFR varied among the selected tumor cell lines (Fig. 2A
, Lane 1), but brief treatment with EGF (100 ng/ml for 5 min) markedly increased tyrosine phosphorylation of EGFR in all four cell lines (Fig. 2A
, compare Lanes 1 and 2). Incubation with ZD1839 for 2 h before EGF stimulation produced a dose-dependent inhibition of EGFR autophosphorylation in all of the tumor cell lines (Fig. 2A
, Lanes 3–8). ZD1839 completely blocked EGF-stimulated EGFR phosphorylation at 0.16 µM in Du145 (prostate) and A549 (lung) cells, whereas complete inhibition was achieved at 0.8 µM in KB (oral squamous) and HT29 (colon) tumor cells.
|
.
Tumor Xenograft Activity.
In athymic nude mice bearing A431-derived xenografts, p.o. treatment once a day with ZD1839 (from day 7 after implantation for 3 weeks) inhibited tumor growth in a dose-dependent manner (Fig. 3)
. The ED50 was 50 mg/kg, and the highest dose, 200 mg/kg ZD1839, prevented tumor growth. Similarly, ZD1839 inhibited the growth of A549 lung (Fig. 3)
and Du145 prostate (Fig. 3)
tumor xenografts in a dose-dependent manner.
|
.
|
. No tumors grew during treatment, but drug withdrawal allowed tumors to grow in five of the eight mice during 44 days of follow-up in this experiment. A more stringent test was provided by tumors that were 1 month old at the start of therapy. ZD1839 treatment (200 mg/kg p.o. once a day) for 90 days produced rapid tumor regression in these more advanced tumors in all mice and, on drug withdrawal, four of six tumors rapidly reestablished (Fig. 5)
.
|
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The requirement for an in vitro test that would distinguish between specific EGFR-TKI-mediated effects on EGF-stimulated growth and serum-stimulated cell growth was recognized at the outset of the drug discovery program and led to the selection for this purpose of the human vulval squamous tumor-derived KB cell line. KB cells grow well in growth factor-depleted medium (i.e., in 5% serum treated with charcoal to deplete growth factors), and addition of EGF increases KB cell growth rate in a reproducible manner. The selectivity of ZD1839 for inhibition of EGF-driven KB cell growth was demonstrated by the large difference in IC50 in the presence or absence of EGF. Cytotoxicity was not observed at ZD1839 concentrations up to 25 µM. The selectivity of ZD1839 for inhibition of EGF-stimulated cell growth was further exemplified in HUVECs. EGF-stimulated growth of HUVECs was potently inhibited by ZD1839, but bFGF- and VEGF-stimulated growth was relatively unaffected by ZD1839 at concentrations that block EGF effects.
Initiation of EGF-stimulated cell growth is triggered by trans autophosphorylation in ligand-binding-activated EGFR/erbB homo- or heterodimers. Western blots of several different human tumor-derived cell lines treated with ZD1839 before brief exposure to EGF showed that ZD1839 blocks EGF-stimulated EGFR autophosphorylation in a dose-dependent and complete manner. Drug washout studies showed that this inhibition is sustained for at least 24 h after a 2-h drug treatment. Other investigators also noted sustained inhibition of autophosphorylation in vitro by ZD1839 after drug washout and attributed this to drug sequestration in cells (12) . More recent studies indicate that quinazoline EGFR-TKIs sequester EGFR into signaling-inactive receptor-ligand complexes (13) .
Other investigators have studied the effects of ZD1839, alone and in combination with other drugs or radiation, on tumor cell proliferation. Ciardiello et al. (14)
demonstrated that ZD1839 inhibits the proliferation of ovarian, breast, and colon cancer cells and provides a synergistic enhancement of the inhibitory action of cytotoxic drugs. The effect of ZD1839 was cytostatic, but higher doses increased apoptotic cell death, and in combination with cytotoxic drugs, ZD1839 markedly enhanced apoptotic cell death. Ciardiello et al. (15)
also showed that ZD1839 inhibits tumor cell synthesis of tumor growth factor 
and of the proangiogenic growth factors VEGF and bFGF. The IC50 for tumor cell growth inhibition by ZD1839 was not strongly influenced by the level of expression of EGFR (14
, 15)
. Preliminary data indicate that combination of ZD1839 with ionizing radiation also has additive or synergistic effects in non-small cell lung cancer cell lines in vitro (16)
. ZD1839 also effectively inhibits the growth of antiestrogen-resistant human breast cancer cells (17)
and human tumor cells that overexpress HER2 (18)
. Additionally, ZD1839 inhibits ERK-1/2 (MAPK) activity, a downstream maker of EGFR signaling, in EGF-dependent human tumor cells at concentrations similar to those that inhibit cell proliferation (19)
.
Testing of drug candidate TKIs for in vivo activity was carried out with xenografts generated from KB cells, which have been used by others to demonstrate in vivo activity of TKIs (20) . This model identified the structural features of quinazolines necessary for in vivo antitumor activity (21) and indicated the importance for in vivo activity of sustaining sufficient drug concentrations in the blood to inhibit EGFR-TK activity throughout each 24-h period after once-a-day dosing (6) . ZD1839 was chosen as a candidate for development because it achieves high and sustained blood levels in vivo over a 24-h period (6) .
The antitumor activity of ZD1839 was demonstrated in tests with tumor xenografts derived from a range of different human tissues. ZD1839 was particularly effective against A431 xenografts, a recognized model for the testing of biological effects on EGFR signaling (22) . ZD1839 inhibited the growth of A431 xenografts in a dose-dependent manner, and complete inhibition was observed in animals receiving a daily p.o. doses of 200 mg/kg ZD1839. Long-term treatment (3–4 months) completely suppressed A431 tumor growth, and withdrawal of drug treatment allowed some tumors to resume growth in the 44-day follow-up period. When ZD1839 treatment was applied to large, well-established A431-derived tumors, rapid tumor regression was observed, which was sustained for the duration of drug treatment (3–4 months). The majority of these tumors resumed growth in the 21-day period after withdrawal of drug treatment, supporting the importance of continuous drug treatment to maintain antitumor activity. No evidence for the development of drug resistance emerged during these studies with A431 tumors because no tumor regrew during long-term ZD1839 treatment.
Dose-dependent tumor growth inhibition by ZD1839 was also demonstrated in mice bearing xenografts of human lung (A549), colon (LoVo, HT29, and HCT15) and prostate (Du145) tumors; additionally, antitumor activity was demonstrated in a breast (MCF-7) and a pancreatic (MIA PaCa-2) model, but some tumors failed to respond to drug treatment [P246 (bronco-epithelial), MKN45 (gastric), and AR42J (pancreatic)]. Review of literature reports on the level of EGFR expression in the cells from which these xenografts were derived reveals a very wide range of expression of EGFR; however, there was no clear correlation between the level of EGFR expression and xenograft sensitivity to ZD1839. Other investigators have also noted that the level of expression of EGFR in cells or tumors did not predict sensitivity to ZD1839 (14 , 23) . The level of EGFR expression may not indicate the degree to which any individual tumor or tumor cell line is dependent on the EGFR signaling pathway for growth. Additional biomarkers that would more specifically indicate this dependence have yet to be defined. Additionally, coexpression of other members of the erbB family that heterodimerize with EGFR but whose signaling would also be inhibited by ZD1839 through its action on the EGFR component of such heterodimers may also play an important role in determining drug sensitivity (18) . Increased EGFR expression is only one mechanism by which enhancement of EGFR signaling drive can be achieved: increased levels of ligand, heterodimerization of EGFR, decreased intracellular phosphatase (which prolongs the activation of EGFR), and mutations in EGFR that lead to constitutive activation of the TK can all contribute to signaling drive. EGFRvIII is a mutated EGFR in which part of the ligand-binding domain of EGFR is missing and the TK is constitutively active. EGFR-TKIs are likely to target this mutant receptor because the kinase domains of EGFRvIII and EGFR are identical.
In addition to the studies reported by Barker et al. (6) discussed above, which indicated the importance to biological activity of sustained exposure to drug throughout the dosing interval (24 h in a once-a-day p.o. dosing regimen), additional biomarker studies were performed in tumor-bearing mice. c-fos transcription represents one end point of EGFR signaling in tumors because c-fos is transiently expressed only in proliferating cells transiting the early, G1 phase of the cell cycle. Reverse transcription-PCR measurements of c-fos mRNA in extracts of A431 tumor xenografts from mice treated with ZD1839 showed that 4 days of drug treatment reduced c-fos in a dose-dependent and complete manner, paralleling drug effects on tumor size. When c-fos was measured in A431 tumors after a single p.o. dose of 50 mg/kg ZD1839, c-fos transcription reached a nadir (5% of control) 6 h after dosing, partially recovered at 24 h (20% of control), and was completely restored at 36 h. Although no complete pharmacokinetic/pharmacodynamic relationship for ZD1839 in the mouse has been defined, these studies indicate that once-a-day p.o. dosing effectively inhibits EGFR signaling throughout the dosing interval and that once-a-day p.o. administration might be a regimen suitable for therapeutic studies in humans.
The studies reported here have indicated the potential utility of ZD1839 as an antitumor agent, but because patients with locally advanced or metastatic cancer undergoing treatment with cytotoxic chemotherapy are most often the target population in which new anticancer agents are tested, combinations of ZD1839 with various cytotoxic drugs with different mechanisms of action have been investigated. These studies showed that combining ZD1839 with platins (cisplatin, oxaliplatin, carboplatin), taxanes (paclitaxel, docetaxel), and topoisomerase inhibitors (doxorubicin, etoposide, topotecan) or the antimetabolite raltitrexed markedly potentiated cytotoxic drug activity in vitro and in vivo (14 , 23) . They also suggest that the addition of ZD1839 to the treatment regimen for patients undergoing cytotoxic chemotherapy might confer significant additional clinical benefits.
In conclusion, these studies demonstrate the potential of ZD1839 (Iressa) in the treatment of many tumors and indicate that continuous once-a-day p.o. dosing may be a suitable therapeutic regimen.
|
FOOTNOTES |
|---|
1 To whom requests for reprints should be addressed, at Department of Cancer and Infection Research, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom. Phone: 44 1625 515116; Fax: 44 1625 513624. 
2 Iressa is a trademark of the AstraZeneca group of companies.
3 The abbreviations used are: EGFR, epidermal growth factor receptor; TK, tyrosine kinase; TKI, tyrosine kinase inhibitor; RTK, receptor tyrosine kinase; MEK, mitogen-activated protein/extracellular signal-related kinase kinase; ERK, extracellular signal-related kinase; MAPK, mitogen-activated protein kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; HUVEC, human umbilical vascular endothelial cell; FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor; TGF, transforming growth factor .
Received . Accepted 8/16/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res., 61: 6500-6510, 2001.This article has been cited by other articles:
|
|
 |
|
  A. J. Gonzales, K. E. Hook, I. W. Althaus, P. A. Ellis, E. Trachet, A. M. Delaney, P. J. Harvey, T. A. Ellis, D. M. Amato, J. M. Nelson, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor Mol. Cancer Ther., July 1, 2008; 7(7): 1880 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Jeong, M. S. Kim, H. K. Nam, C. K. Min, S. Lee, Y. J. Chung, N. J. Yoo, and S. H. Lee Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers Clin. Cancer Res., June 15, 2008; 14(12): 3716 - 3721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ren, B. Korchin, Q.-S. Zhu, C. Wei, A. Dicker, J. Heymach, A. Lazar, R. E. Pollock, and D. Lev Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo Clin. Cancer Res., May 1, 2008; 14(9): 2785 - 2795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Soeda, A. Inagaki, N. Oka, Y. Ikegame, H. Aoki, S.-i. Yoshimura, S. Nakashima, T. Kunisada, and T. Iwama Epidermal Growth Factor Plays a Crucial Role in Mitogenic Regulation of Human Brain Tumor Stem Cells J. Biol. Chem., April 18, 2008; 283(16): 10958 - 10966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Dougherty, A. Sehdev, S. Cerda, R. Mustafi, N. Little, W. Yuan, S. Jagadeeswaran, A. Chumsangsri, J. Delgado, M. Tretiakova, et al. Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model Clin. Cancer Res., April 15, 2008; 14(8): 2253 - 2262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Okabe, I. Okamoto, S. Tsukioka, J. Uchida, T. Iwasa, T. Yoshida, E. Hatashita, Y. Yamada, T. Satoh, K. Tamura, et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase Mol. Cancer Ther., March 1, 2008; 7(3): 599 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Benedetti, P. Perego, G. Luca Beretta, E. Corna, S. Tinelli, S. C. Righetti, R. Leone, P. Apostoli, C. Lanzi, and F. Zunino Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds Mol. Cancer Ther., March 1, 2008; 7(3): 679 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanaka, A. Munshi, C. Brooks, J. Liu, M. L. Hobbs, and R. E. Meyn Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity Clin. Cancer Res., February 15, 2008; 14(4): 1266 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang, P. Guo, X. Wang, Q. Zhou, and J. M. Gallo Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models Mol. Cancer Ther., February 1, 2008; 7(2): 407 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Emanuel, T. V. Hughes, M. Adams, C. A. Rugg, A. Fuentes-Pesquera, P. J. Connolly, N. Pandey, S. Moreno-Mazza, J. Butler, V. Borowski, et al. Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors Mol. Pharmacol., February 1, 2008; 73(2): 338 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al. Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib Cancer Res., January 15, 2008; 68(2): 571 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Krol, R. E. Francis, A. Albergaria, A. Sunters, A. Polychronis, R. C. Coombes, and E. W.-F. Lam The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells Mol. Cancer Ther., December 1, 2007; 6(12): 3169 - 3179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Janne, J. von Pawel, R. B. Cohen, L. Crino, C. A. Butts, S. S. Olson, I. A. Eiseman, A. A. Chiappori, B. Y. Yeap, P. F. Lenehan, et al. Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2007; 25(25): 3936 - 3944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Smith, G. Walsh, A. Skene, A. Llombart, J. I. Mayordomo, S. Detre, J. Salter, E. Clark, P. Magill, and M. Dowsett A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer J. Clin. Oncol., September 1, 2007; 25(25): 3816 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yamasaki, D. Zhang, C. Bartholomeusz, T. Sudo, G. N. Hortobagyi, K. Kurisu, and N. T. Ueno Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity Mol. Cancer Ther., August 1, 2007; 6(8): 2168 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rosano, V. Di Castro, F. Spinella, G. Tortora, M. R. Nicotra, P. G. Natali, and A. Bagnato Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity Cancer Res., July 1, 2007; 67(13): 6351 - 6359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Tsao, D. He, B. Saigal, S. Liu, J. J. Lee, S. Bakkannagari, N. G. Ordonez, W. K. Hong, I. Wistuba, and F. M. Johnson Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion Mol. Cancer Ther., July 1, 2007; 6(7): 1962 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yamasaki, M. J. Johansen, D. Zhang, S. Krishnamurthy, E. Felix, C. Bartholomeusz, R. J. Aguilar, K. Kurisu, G. B. Mills, G. N. Hortobagyi, et al. Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt Cancer Res., June 15, 2007; 67(12): 5779 - 5788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Olejniczak, C. Van Sant, M. G. Anderson, G. Wang, S. K. Tahir, G. Sauter, R. Lesniewski, and D. Semizarov Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains Mol. Cancer Res., April 1, 2007; 5(4): 331 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Stadler The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents Mol. Cancer Ther., April 1, 2007; 6(4): 1180 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Daniele, L. Macri, M. Schena, D. Dongiovanni, L. Bonello, E. Armando, L. Ciuffreda, O. Bertetto, G. Bussolati, and A. Sapino Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens Mol. Cancer Ther., April 1, 2007; 6(4): 1223 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. Sequist Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Oncologist, March 1, 2007; 12(3): 325 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. Sequist, D. W. Bell, T. J. Lynch, and D. A. Haber Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non-Small-Cell Lung Cancer J. Clin. Oncol., February 10, 2007; 25(5): 587 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fichera, N. Little, S. Jagadeeswaran, U. Dougherty, A. Sehdev, R. Mustafi, S. Cerda, W. Yuan, S. Khare, M. Tretiakova, et al. Epidermal Growth Factor Receptor Signaling Is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis Cancer Res., January 15, 2007; 67(2): 827 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yan, Y. Lu, M. Wang, H. Vikis, R. Yao, Y. Wang, R. A. Lubet, and M. You Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer Mol. Cancer Res., December 1, 2006; 4(12): 971 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E Jones, J. M W Gee, I. R Hutcheson, J. M Knowlden, D. Barrow, and R. I Nicholson Growth factor receptor interplay and resistance in cancer Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S45 - S51. [Abstract] [Full Text] [PDF]
|
|
) or ZD1839 [3.125 mg/kg (
), 12.5 mg/kg (
), 50 mg/kg (
), or 200 mg/kg (
)] was administered by oral gavage once daily. Data are expressed as mean (bars, SD) tumor volume.
